Trial Profile
A Phase 2, Randomised, Placebo Controlled Study Investigating the Efficacy of Baricitinib in New Onset Type 1 Diabetes Mellitus
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Dec 2023
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Acronyms BANDIT
- 07 Dec 2023 Results published in the New England Journal of Medicine.
- 06 Oct 2023 Primary endpoint (The primary endpoint of the study is the change from baseline of plasma C-peptide area under the curve (AUC) over 2 hours following a mixed meal.) has been met, as per results presented at the 59th Annual Meeting of the European Association for the Study of Diabetes.
- 06 Oct 2023 Results assessing to preserve the bodys ability to make insulin rather than improve how a lack of insulin is managed, presented at the 59th Annual Meeting of the European Association for the Study of Diabetes.